Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development

Clinical Genitourinary Cancer

Volumn 16, Issue 2, 2018, Pages 117-129

  Powles, Thomas ^a   Necchi, Andrea ^b   Rosen, Galit ^c   Hariharan, Subramanian ^d   Apolo, Andrea B ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c EMD SERONO INC   (United States)

^d PFIZER INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; CD274; Clinical trials; Immunotherapy; Urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; CHECKPOINT KINASE INHIBITOR; CISPLATIN; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT-REPORTED OUTCOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85044572822     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2017.11.002     Document Type: Review

References (75)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: bladder cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html Accessed: July 6, 2017.
2. International Agency for Research on Cancer. Cancer today. Available at: http://gco.iarc.fr/today Accessed: August 24, 2017.
3. International Agency for Research on Cancer. GLOBOCAN 2012: cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr Accessed: April 7, 2017.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Bladder cancer. v5. 2017.
5. Kaufman, D., Raghavan, D., Carducci, M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000), 1921–1927.
6. von der Maase, H., Hansen, S.W., Roberts, J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000), 3068–3077.
7. Apolo, A.B., Ostrovnaya, I., Halabi, S., et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 105 (2013), 499–503.
8. Necchi, A., Sonpavde, G., Lo Vullo, S., et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Eur Urol 71 (2017), 281–289.
9. Necchi, A., Pond, G.R., Raggi, D., et al. Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 15 (2017), 23–30.
10. Vaughn, D.J., Srinivas, S., Stadler, W.M., et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115 (2009), 4110–4117.
11. Bellmunt, J., Theodore, C., Demkov, T., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009), 4454–4461.
12. Raggi, D., Miceli, R., Sonpavde, G., et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27 (2016), 49–61.
13. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
14. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer–immunity cycle. Immunity 39 (2013), 1–10.
15. Morales, A., Eidinger, D., Bruce, A.W., Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976), 180–183.
16. TheraCys (BCG live), intravesicle [prescribing information]. Toronto, ON, Canada: Sanofi Pasteur Limited; 2013.
17. Fuge, O., Vasdev, N., Allchorne, P., Green, J.S., Immunotherapy for bladder cancer. Res Rep Urol 7 (2015), 65–79.
18. Buchbinder, E.I., Desai, A., CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39 (2016), 98–106.
19. Tecentriq (atezolizumab) injection [prescribing information]. South San Francisco, CA: Genentech Inc; 2016.
20. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
21. Opdivo (nivolumab) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2017.
22. Sharma, P., Retz, M., Siefker-Radtke, A., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 (2017), 312–322.
23. Massard, C., Gordon, M.S., Sharma, S., et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand–1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
24. Imfinzi (durvalumab) injection [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
25. Apolo, A.B., Infante, J.R., Balmanoukian, A., et al. Avelumab, an anti–programmed death–ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study. J Clin Oncol 35 (2017), 2117–2124.
26. Bavencio (avelumab) injection [prescribing information]. Darmstadt, Germany: Merck KGaA; 2017.
27. Bellmunt, J., de Wit, R., Vaughn, D.J., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
28. Keytruda (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc; 2017.
29. Balar, A.V., Galsky, M.D., Rosenberg, J.E., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
30. Balar, A., Bellmunt, J., O'Donnell, P.H., et al. Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population. J Clin Oncol, 35(suppl), 2017 (abstract 284).
31. Blake, S.J., Ching, A.L., Kenna, T.J., et al. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One, 10, 2015, e0119483.
32. Dirks, J., Egli, A., Sester, U., Sester, M., Hirsch, H.H., Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells. Transpl Infect Dis 15 (2013), 79–89.
33. Scheel, A.H., Dietel, M., Heukamp, L.C., et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29 (2016), 1165–1172.
34. Apolo, A., PDL1: the illusion of an ideal biomarker. EU Focus 1 (2016), 269–271.
35. Loriot, Y., Rosenberg, J., Powles, T., et al. Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the ph II IMvigor210 study. Ann Oncol 27 (2016), 266–295.
36. Ma, W., Gilligan, B.M., Yuan, J., Li, T., Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol, 9, 2016, 47.
37. Petrylak, D.P., Powles, T., Bellmunt, J., et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol, 33(suppl), 2015 (abstract 4501).
38. Sharma, P., Callahan, M.K., Bono, P., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (2016), 1590–1598.
39. Powles, T., O'Donnell, P.H., Massard, C., et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol, 3, 2017, e172411.
40. Apolo, A.B., Ellerton, J., Infante, J., et al. Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): pooled analysis from 2 cohorts of the phase 1b JAVELIN solid tumor study. J Clin Oncol, 35(suppl), 2017 (abstract 4528).
41. Plimack, E.R., Bellmunt, J., Gupta, S., et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18 (2017), 212–220.
42. Powles, T., Loriot, Y., Duran, I., et al. IMvigor211: a phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma [abstract 606]. Paper presented at: 2nd Special Conference of the European Association for Cancer Research–American Association for Cancer Research–Italian Cancer Society Special Conference; June 24-28, 2017; Florence, Italy. Available at: http://www.ecco-org.eu/en/Events/EAS2017/Searchable-Programme#anchorScpr Accessed: December 29, 2017.
43. Bajorin, D.F., de Wit, R., Vaugh, D.J., et al. Planned survival analysis from KEYNOTE-045: phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). J Clin Oncol, 35(suppl), 2017 (abstract 4501).
44. Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti–PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
45. Bellmunt, J., Choueiri, T.K., Fougeray, R., et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28 (2010), 1850–1855.
46. Bellmunt, J., Mottet, N., De Santis, M., Urothelial carcinoma management in elderly or unfit patients. EJC Suppl 14 (2016), 1–20.
47. O'Donnell, P.H., Grivas, P., Balar, A.V., et al. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol, 35(suppl), 2017 (abstract 4502).
48. Sharma, P., Callahan, M., Calvo, E., et al. Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: first results from the phase I/II CheckMate 032 study. J Clin Oncol, 34(suppl), 2016 (abstract 4501).
49. Apolo, A.B., Mortazavi, A., Stein, M.N., et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CapoNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors. J Clin Oncol, 35(suppl), 2017 (abstract 4562).
50. Petrylak, D.P., Arkenau, H.-T., Perez-Gracia, J.L., et al. A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): interim safety and clinical activity in patients with urothelial carcinoma. J Clin Oncol, 35(suppl), 2017 (abstract 349).
51. Lara, P., Beckett, L., Li, Y., et al. Combination checkpoint immunotherapy and cytotoxic chemotherapy: pembrolizumab (pembro) plus either docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer. J Clin Oncol, 35(suppl), 2017 (abstract 398).
52. Smith, D.C., Gajewski, T.F., Hamid, O., et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase 1/2 results of ECHO-202/KEYNOTE-037. J Clin Oncol, 35(suppl), 2017 (abstract 4503).
53. Postow, M.A., Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 2015, 76–83.
54. Koyama, S., Akbay, E.A., Li, Y.Y., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 7, 2016, 10501.
55. Powles, T., Gschwend, J.E., Loriot, Y., et al. Phase 3 KEYNOTE-361 trial: pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. J Clin Oncol, 35(suppl), 2017 (abstract TPS4590).
56. ClinicalTrials.gov. Study of nivolumab in combination with ipilimumab or standard of care chemotherapy compared to the standard of care chemotherapy alone in treatment of patients with untreated inoperable or metastatic urothelial cancer (CheckMate901). Available at: https://clinicaltrials.gov/ct2/show/NCT03036098 Accessed: November 11, 2017.
57. Park, S.H., Castellano, D., Petrylak, D.P., et al. A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable stage IV urothelial bladder cancer (UBC): DANUBE. Ann Oncol, 27(suppl), 2016 (abstract 285TiP).
58. ClinicalTrials.gov. Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130). Available at: https://clinicaltrials.gov/ct2/show/NCT02807636 Accessed: June 1, 2017.
59. Garcia-Donas, J., Font, A., Perez-Valderama, B., et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicenter, randomised, controlled, open-label, phase 2 trial. Lancet Oncol 18 (2017), 672–681.
60. ClinicalTrials.gov. Testing the PD-1 inhibitor pembrolizumab as maintenance therapy after initial chemotherapy in metastatic bladder cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02500121 Accessed: June 1, 2017.
61. Powles, T., Grivas, P., Aragon-Ching, J.B., et al. A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as a maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Ann Oncol, 27(suppl), 2016 (abstract 842TiP).
62. ClinicalTrials.gov. Open-label, randomised, multi-drug, biomarker-directed, phase 1b study in pts w/ muscle invasive bladder cancer (BISCAY). Available at: https://clinicaltrials.gov/show/NCT02546661 Accessed: November 1, 2017.
63. Apolo, A.B., Grossman, H.B., Bajorin, D., Steinberg, G., Kamat, A.M., Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 30 (2012), 772–780.
64. ClinicalTrials.gov. Preoperative MPDL3280A in transitional cell carcinoma of the bladder (ABACUS). Available at: https://clinicaltrials.gov/ct2/show/NCT02662309 Accessed: June 1, 2017.
65. ClinicalTrials.gov. Neoadjuvant pembrolizumab for muscle-invasive urothelial bladder carcinoma. Available at: https://clinicaltrials.gov/ct2/show/NCT02736266 Accessed: June 1, 2017.
66. ClinicalTrials.gov. An investigational immuno-therapy study of nivolumab, compared to placebo, in patients with bladder or upper urinary tract cancer, following surgery to remove the cancer (CheckMate 274). Available at: https://clinicaltrials.gov/ct2/show/NCT02632409 Accessed: June 1, 2017.
67. ClinicalTrials.gov. Phase III randomized adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) versus observation. Available at: https://clinicaltrials.gov/ct2/show/NCT03244384 Accessed: November 1, 2017.
68. Rimm, D.L., Han, G., Taube, J.M., et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer. JAMA Oncol 3 (2017), 1051–1058.
69. Hirsch F, Averbuch S, McCaffery I, et al. The Blueprint Project: harmonizing companion diagnostics across a class of targeted therapies. Paper presented at: AACR Annual Meeting; April 16-20, 2016; New Orleans, LA.
70. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
71. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
72. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
73. Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111 (2014), 3110–3115.
74. Vaughn, D.J., Bellmunt, J., De Wit, R., et al. Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol, 35(suppl), 2017 (abstract 282).
75. Alexander, W., The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 41 (2016), 185–191.